SRX 0.00% $33.55 sirtex medical limited

SRX is a buy (imo)

  1. 25,374 Posts.
    lightbulb Created with Sketch. 2
    Been a bit liverish myself

    Chianti jokes aside

    Liver cancer is going to reach epidemic proportions 20yrs HCV Hep C incubation time, the sixties has caught me up, for one.

    on the Sirtex website

    ASX Announcements

    The following announcements have recently been made to the Australian Stock Exchange (ASX)

    21-06-02 Results of Studies Published in Scientific Journals

    18-06-02 Patients Treated at William Beaumont Hospital in Detroit

    12-06-02 Sirtex Presents at Merrill Lynch Conference, Sydney

    24-05-02 First Patient Treated in USA

    20-05-02 Clinical Trial Results Released

    02-05-02 Northern Hemisphere Supply Agreement

    12-04-02 Appendix 4C Quarterly Report

    14-03-02 Clinical Trial Collaboration with Pharmacia and Sanofi Synthelabo

    07-03-02 Appendix 4B - Half Yearly Results Dec 01

    07-03-02 Final FDA Approval for SIR-Spheres

    05-03-02 Correction to December Quarterly Cash Flow


    Press Release

    Peoria Man Becomes First U.S. Recipient of New Procedure for Metastatic Liver Cancer

    Australian-developed SIRT received FDA approval in March; first U.S. procedure performed at Good Samaritan Regional Medical Center

    PHOENIX - A Peoria man became the first North American recipient of a recently approved treatment for inoperable metastatic liver cancer at Good Samaritan Regional Medical Center. Brian Anderson, 30 and diagnosed with colorectal cancer that metastasized to his liver, underwent a new radiation procedure called Selective Internal Radiation Therapy (SIRT) on Wednesday, May 22.

    Developed by the Australian firm SIRTeX Medical Ltd., SIRT involves the placement of a catheter in the femoral artery of the upper thigh and threaded through the hepatic artery, the major blood vessel of the liver, to the location of the tumor. Millions of microscopic radioactive spheres called SIR-Spheres® are delivered to the tumor through the catheter. The microspheres, each approximately 35 microns (the size of four red blood cells), are bonded to yttrium-90 (Y-90), a pure beta emitter with a physical half-life of 64.2 hours (about 2.68 days). The microspheres are trapped in the tumor’s capillary bed, where they burn away the tumor from inside. The average range of the radiation is 2.5 mm (one-tenth of an inch). The SIR-Spheres® remain inside the body, where the isotope decays into stable zirconium-90. After 14 days, only 2.5 percent of the radioactive activity remains.

    Charles Nutting, DO, chief of Interventional Radiology at Good Samaritan, conducted the SIRT procedure with assistance from Australian liver surgeon Bruce Gray, MD, medical director for SIRTeX who has performed more than 300 such procedures. The radiation was delivered by Calvin Lutrin, MD, director of Nuclear Medicine at Good Samaritan.

    Colorectal cancer affects nearly 140,000 people in the U.S.; almost half of those will redevelop the cancer in the liver within five years. Spread of the cancer to the liver is the major cause of mortality in these patients.

    “Cases like Mr. Anderson’s are, unfortunately, too common,” said Dr. Nutting. “Cells from colorectal and other cancerous tumors, by nature, will break away from the main tumor mass. These cancerous cells are carried away by both the body’s circulatory system and the lymph system. What can happen is that portions of that cancer can metastasize, or redevelop, in other areas of the body. The liver is the body’s largest filter and often these cancers will metastasize in the liver.

    “The current therapy for a secondary liver cancer is chemotherapy and a surgical resection if the tumor is confined to a small area; however only 20 percent of patients fall into that category, due to the size of the tumor, the location or other factors,” Dr. Nutting added. “Prior to SIRT, the options for patients like Mr. Anderson involved chemotherapy and/or chemo-embolization, neither of which works particularly well. Typically, those people become fairly sick during the recovery period. Radio-frequency ablation (RFA) is a new alternative treatment for some of the smaller lesions, however RFA is usually only good on tumors that are less than 5 cm in size.”

    A recent Australian trial showed that SIRT, when used in conjunction with chemotherapy, saw a 91-percent response rate. The study also showed that SIRT could prevent the tumor from growing for a greater amount of time. It took an average 4.7 months before the tumor resumed growth in patients treated with chemotherapy alone, compared to 15.6 months for patients receiving the SIR-­Spheres®.

    In several cases, the SIRT procedure has reduced the size of the tumor so that doctors can perform a resection of the liver. In other cases, the combination of tumor reduction and extended time allowed the patient became a candidate for a liver transplant, making SIRT a bridge to a total cure.

    SIRT is performed as an outpatient procedure, so patients will be able to go home that day. Additionally, there are fewer risks and side effects to the procedure for the patient compared to the chemotherapies, and little radiation risk to family members or other persons, Dr. Nutting added.

    SIRT received approval from the U.S. Food and Drug Administration (FDA) on March 7, 2002, for the treatment of malignant metastatic liver tumors secondary to large bowel cancer that cannot be treated surgically. The FDA granted SIRTeX, manufacturer of SIR-Sphere®, a Pre-Market Approval (PMA) based on the results of very positive clinical trials in Australia. More than 900 patients in Australia, New Zealand, Hong Kong, Singapore and Thailand have been treated with SIRT.

    Good Samaritan is a leader in using intravascular radiation for the treatment of liver cancers. The hospital has been using a similar procedure called Thera-Sphere for treatment of primary hepatocellular carcinoma (HCC) to slow the tumor growth and allow a patient more time before a donated organ can be found. On Nov. 25, 2001, Good Samaritan transplant surgeons performed the first liver transplant for a Thera-Sphere patient.

    Good Samaritan is Arizona’s largest and busiest medical center. Located in downtown Phoenix, Good Samaritan has been providing medical care since 1911. Today, nearly 2,000 physicians representing nearly 50 specialties work with Good Samaritan staff to provide care to more than 34,000 inpatients a year.

watchlist Created with Sketch. Add SRX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.